Lynch, K., Chapman, R., Keshav, S., Montano-Loza, A., Mason, A., Kremer, A., . . . Levy, C. (2019). Effects of vedolizumab in patients with primary sclerosing cholangitis and inflammatory bowel diseases. Elsevier.
Čikaški stil citiranja (17. izdanje)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
MLA način citiranja (9. izdanje)Lynch, K., et al. Effects of Vedolizumab in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. Elsevier, 2019.
Upozorenje: Ovi citati možda nisu uvijek 100% točni.